ID

31597

Beschrijving

Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002); ODM derived from: https://clinicaltrials.gov/show/NCT00777959

Link

https://clinicaltrials.gov/show/NCT00777959

Trefwoorden

  1. 10-09-18 10-09-18 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

10 september 2018

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0

Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Prostate Cancer NCT00777959

Eligibility Prostate Cancer NCT00777959

Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
confirmed adenocarcinomas of the prostate.
Beschrijving

Adenocarcinoma of prostate

Datatype

boolean

Alias
UMLS CUI [1]
C0007112
evidence of metastatic disease
Beschrijving

Neoplasm Metastasis

Datatype

boolean

Alias
UMLS CUI [1]
C0027627
evidence of disease progression including one of the following: increasing levels of psa, progressive lymph node disease, or worsening bone scan
Beschrijving

Disease Progression | Raised prostate specific antigen | Disorder of lymph node Progressive | Bone scan Worsening

Datatype

boolean

Alias
UMLS CUI [1]
C0242656
UMLS CUI [2]
C0178415
UMLS CUI [3,1]
C0272394
UMLS CUI [3,2]
C0205329
UMLS CUI [4,1]
C0203668
UMLS CUI [4,2]
C0332271
psa level is greater or equal to 7 ng/ml.
Beschrijving

Prostate specific antigen measurement

Datatype

boolean

Alias
UMLS CUI [1]
C0201544
ecog performance status less than or equal to 1
Beschrijving

ECOG performance status

Datatype

boolean

Alias
UMLS CUI [1]
C1520224
exclusion criteria :
Beschrijving

Exclusion Criteria

Datatype

boolean

Alias
UMLS CUI [1]
C0680251
previously received bicalutamide, flutamide, or nilutamide within the past 12 months (except for a period of use less than 30 days long).
Beschrijving

bicalutamide | Flutamide | nilutamide

Datatype

boolean

Alias
UMLS CUI [1]
C0285590
UMLS CUI [2]
C0016384
UMLS CUI [3]
C0068771
prior chemotherapy for prostate cancer
Beschrijving

Prior Chemotherapy Prostate carcinoma

Datatype

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C0600139
prior rapamycin or rapamycin analogs, including ridaforolimus, everolimus, or temsirolimus.
Beschrijving

Sirolimus | Sirolimus Analogs | ridaforolimus | everolimus | temsirolimus

Datatype

boolean

Alias
UMLS CUI [1]
C0072980
UMLS CUI [2,1]
C0072980
UMLS CUI [2,2]
C0243071
UMLS CUI [3]
C2713007
UMLS CUI [4]
C0541315
UMLS CUI [5]
C1707080
patient is receiving an opioid or narcotic analgesic for pain due to prostate cancer
Beschrijving

Opioids Pain | Narcotic Analgesics Pain | Pain Due to Prostate carcinoma

Datatype

boolean

Alias
UMLS CUI [1,1]
C0242402
UMLS CUI [1,2]
C0030193
UMLS CUI [2,1]
C0027409
UMLS CUI [2,2]
C0030193
UMLS CUI [3,1]
C0030193
UMLS CUI [3,2]
C0678226
UMLS CUI [3,3]
C0600139
patient has pain related to prostate cancer that warrants the initiation of chemotherapy
Beschrijving

Pain Relationship Prostate carcinoma | Initiation Chemotherapy Required

Datatype

boolean

Alias
UMLS CUI [1,1]
C0030193
UMLS CUI [1,2]
C0439849
UMLS CUI [1,3]
C0600139
UMLS CUI [2,1]
C1704686
UMLS CUI [2,2]
C0392920
UMLS CUI [2,3]
C1514873

Similar models

Eligibility Prostate Cancer NCT00777959

Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Adenocarcinoma of prostate
Item
confirmed adenocarcinomas of the prostate.
boolean
C0007112 (UMLS CUI [1])
Neoplasm Metastasis
Item
evidence of metastatic disease
boolean
C0027627 (UMLS CUI [1])
Disease Progression | Raised prostate specific antigen | Disorder of lymph node Progressive | Bone scan Worsening
Item
evidence of disease progression including one of the following: increasing levels of psa, progressive lymph node disease, or worsening bone scan
boolean
C0242656 (UMLS CUI [1])
C0178415 (UMLS CUI [2])
C0272394 (UMLS CUI [3,1])
C0205329 (UMLS CUI [3,2])
C0203668 (UMLS CUI [4,1])
C0332271 (UMLS CUI [4,2])
Prostate specific antigen measurement
Item
psa level is greater or equal to 7 ng/ml.
boolean
C0201544 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status less than or equal to 1
boolean
C1520224 (UMLS CUI [1])
Exclusion Criteria
Item
exclusion criteria :
boolean
C0680251 (UMLS CUI [1])
bicalutamide | Flutamide | nilutamide
Item
previously received bicalutamide, flutamide, or nilutamide within the past 12 months (except for a period of use less than 30 days long).
boolean
C0285590 (UMLS CUI [1])
C0016384 (UMLS CUI [2])
C0068771 (UMLS CUI [3])
Prior Chemotherapy Prostate carcinoma
Item
prior chemotherapy for prostate cancer
boolean
C1514457 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
Sirolimus | Sirolimus Analogs | ridaforolimus | everolimus | temsirolimus
Item
prior rapamycin or rapamycin analogs, including ridaforolimus, everolimus, or temsirolimus.
boolean
C0072980 (UMLS CUI [1])
C0072980 (UMLS CUI [2,1])
C0243071 (UMLS CUI [2,2])
C2713007 (UMLS CUI [3])
C0541315 (UMLS CUI [4])
C1707080 (UMLS CUI [5])
Opioids Pain | Narcotic Analgesics Pain | Pain Due to Prostate carcinoma
Item
patient is receiving an opioid or narcotic analgesic for pain due to prostate cancer
boolean
C0242402 (UMLS CUI [1,1])
C0030193 (UMLS CUI [1,2])
C0027409 (UMLS CUI [2,1])
C0030193 (UMLS CUI [2,2])
C0030193 (UMLS CUI [3,1])
C0678226 (UMLS CUI [3,2])
C0600139 (UMLS CUI [3,3])
Pain Relationship Prostate carcinoma | Initiation Chemotherapy Required
Item
patient has pain related to prostate cancer that warrants the initiation of chemotherapy
boolean
C0030193 (UMLS CUI [1,1])
C0439849 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,3])
C1704686 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C1514873 (UMLS CUI [2,3])

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial